What is it used for?
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product LAGEVRIO™ for treatment of adults with mild-to-moderate coronavirus disease 2019 (COVID-19): who are at high risk for progression to severe COVID-19, including hospitalization or death. Refer to CDC website https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html . Healthcare providers should consider the benefit-risk for an individual patient. for additional details, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. LIMITATIONS OF AUTHORIZED USE LAGEVRIO is not authorized for use …The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product LAGEVRIO™ for treatment of adults with mild-to-moderate coronavirus disease 2019 (COVID-19): who are at high risk for progression to severe COVID-19, including hospitalization or death. Refer to CDC website https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html . Healthcare providers should consider the benefit-risk for an individual patient. for additional details, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. LIMITATIONS OF AUTHORIZED USE LAGEVRIO is not authorized for use …
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- molnupiravirmolnupiravir
- Form and strength
- CAPSULE · 200 mgCAPSULE · 200 mg
- Manufacturer / applicant
- MERCK SHARP & DOHME LLCMERCK SHARP & DOHME LLC
Capsules: 200 mg, Swedish Orange opaque size 0 capsules. The capsules have the corporate logo and “82” printed in white ink.Capsules: 200 mg, Swedish Orange opaque size 0 capsules. The capsules have the corporate logo and “82” printed in white ink.
Safety and clinical review
MANDATORY REQUIREMENTS FOR ADMINISTRATION OF LAGEVRIO UNDER EMERGENCY USE AUTHORIZATION In order to mitigate the risks of using this unapproved product under the EUA and to optimize the potential benefit of LAGEVRIO, the following steps are required. Use of LAGEVRIO under this …MANDATORY REQUIREMENTS FOR ADMINISTRATION OF LAGEVRIO UNDER EMERGENCY USE AUTHORIZATION In order to mitigate the risks of using this unapproved product under the EUA and to optimize the potential benefit of LAGEVRIO, the following steps are required. Use of LAGEVRIO under this …
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
- Hypersensitivity Including AnaphylaxisHypersensitivity Including Anaphylaxis
- Bone and Cartilage ToxicityBone and Cartilage Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is LAGEVRIO used for?
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product LAGEVRIO™ for treatment of adults with mild-to-moderate coronavirus disease 2019 (COVID-19): who are at high risk for progression to severe COVID-19, including hospitalization or death. Refer to CDC website https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html . Healthcare providers should consider the benefit-risk for an individual patient. for additional details, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. LIMITATIONS OF AUTHORIZED USE LAGEVRIO is not authorized for use …The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product LAGEVRIO™ for treatment of adults with mild-to-moderate coronavirus disease 2019 (COVID-19): who are at high risk for progression to severe COVID-19, including hospitalization or death. Refer to CDC website https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html . Healthcare providers should consider the benefit-risk for an individual patient. for additional details, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. LIMITATIONS OF AUTHORIZED USE LAGEVRIO is not authorized for use …
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of LAGEVRIO should I ask about?
CAPSULE · 200 mgCAPSULE · 200 mg
Read the primary sourceWhat determines the price of LAGEVRIO?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using LAGEVRIO?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.